The GOG Foundation, Inc. (GOG-F) announced the new IDEA Commitment initiative on Thursday, February 15, 2024 at the NRG Semi-Annual Meeting in Orlando, Florida.

The GOG-F has invested in the IDEA Commitment to:
- Increase awareness about the importance of diversity in clinical trials,
- Identify barriers to enrolling underrepresented patients,
- And design clinical trials in partnership with industry that demonstrate a commitment to inclusion, diversity, equity and access for all patients.

The IDEA Commitment efforts of improving diversity in clinical trials will focus on Education, Access, Policy, and Research.

Click the video below to view the Welcome & Introduction to the IDEA Commitment with Dr. Thomas Herzog, President of The GOG Foundation, Inc., and Dr. Bhavana Pothuri, Director of Diversity & Health Equity for Clinical Trials for The GOG Foundation, Inc.
The Society of Gynecologic Oncology (SGO) and The GOG Foundation, Inc. (GOG-F) Launch the BRIDGES 2.0 Research Initiative with support from the Foundation for Women's Cancer (FWC).

After a successful inaugural year, the SGO and the GOG-F join forces to collaborate and proudly announce the launch of an expanded two-year clinical trial education program supported by the FWC. This important career and clinical trial development initiative aims to cultivate the next generation of investigators in gynecologic oncology and will focus on clinical and translational research advancements, trial methodology, and real world clinical trials implementation.

BRIDGES 2.0 is tailored for gynecologic oncologists, medical oncologists, and radiation oncologists in the early stages of their careers, including senior fellows and faculty members with less than ten years of experience post-training, to gain critical insights into clinical trial design fundamentals.

Applications are actively being accepted as of today. Interested candidates can find a comprehensive outline of application requirements on the BRIDGES webpage. Prospective applicants are encouraged to prepare submissions early to ensure receipt by the deadline of Thursday, May 16, 2024.

The selected cohort of BRIDGES 2.0 scholars will begin their program engagement in July 2024 at the NRG Semi-Annual Meeting, July 25-27, 2024 in Denver, Colorado.
CERVICAL CANCER GEO-ANALYZER

The Cervical Cancer Geo-Analyzer is an open access, web-based, interactive tool to visualize cervical cancer and r/mCC burden across different communities in the United States. The tool aims to help researchers, policy makers, and advocacy groups inform geographical areas in the United States where cervical cancer education or healthcare resource needs are high. For building the user interface, we utilized free and open-source ReactJS software.

“My hope is that the Cervical Cancer Geo-Analyzer will lead to a better understanding of geographic interactions and impact on how, where, and when patients get cancer treatments. To describe the unique barriers at geographic level such that resources, policy initiatives, and clinical trial portfolios can be tailored to specific community and regional needs,” said Tara Castellano, MD, University Medical Center New Orleans Health, New Orleans, Louisiana, USA.

For additional information, please see the related article published in Gynecologic Oncology here.

Access the Geo-Analyzer

IN THE NEWS

GOG-3091 (VB C-04) Press Release

Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Oslo, Norway, April 19, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq®) in patients with HPV16-positive, PD-L1-positive, recurrent, or metastatic cervical cancer.

Click here to view the full press release.

ENGOT-EN6-NSGO / GOG-3031 RUBY Press Release

RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer

March 16, 2024 -- The European Network for Gynaecological Oncological Trial (ENGOT) groups, the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU) and the GOG Foundation, Inc. (GOG-F) are proud to collaborate with the study sponsor, GSK
The results reveal improvement in progression-free survival (PFS) at 12 months in the overall study population from 33.7% (carboplatin/paclitaxel [CP]+placebo+placebo) to 57.0% (CP+dostarlimab+niraparib), and in MMRp/MSS population from 31.1% (CP+placebo+placebo) to 54.7% (CP+dostarlimab+niraparib).

Click here to view the full press release.

ENGOT-cx11 / GOG-3047 KEYNOTE A-18 Press Release

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

March 15, 2024 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) met its primary endpoint of overall survival (OS) for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer.

Click here to view the full press release.

Click the video below to watch the live interview from the 2024 SGO Annual Meeting on Women’s Cancer® with Dr. Ginger Gardner and Dr. Leslie Randall discussing ENGOT-cx11 / GOG-3047 KEYNOTE A-18.

GOG-3020/ENGOT-ov45 ATHENA-MONO Press Release

pharma&’s Rubraca® (rucaparib) ATHENA-MONO Clinical Trial Data in First-Line Maintenance Treatment Suggest Benefit Continues Beyond Completion of Treatment and First Progression

Vienna, Austria, March 16, 2024 – pharmaand GmbH (pharma&) announced today the presentation of data from the randomized, Phase 3 Company-sponsored ATHENA (GOG-3020/ENGOT-ov45) trial (ATHENA-MONO) monotherapy versus placebo presented on Saturday, March 16, 2024, during the Society of Gynecologic Oncology (SGO) Annual Meeting held in San Diego, California, U.S.A. Dr. Rebecca S. Kristeleit MD, PhD, of Guy’s and St Thomas’ NHS Foundation Trust in London and lead ENGOT/NCRI National Cancer Research Institute (https://www.ncri.org.uk/) investigator of the ATHENA trial will present the oral presentation, “Interim Post-Progression Data and Updated Survival in Patients with Newly Diagnosed Advanced Ovarian Cancer in ATHENA-MONO.”

Click here to view the full press release.
Kathleen Moore, MD, MS announced 2023 recipient of the Rosalind Franklin Prize for Excellence in Ovarian Cancer Research

The 2023 recipient of the Rosalind Franklin Prize for Excellence in Ovarian Cancer Research is Kathleen N. Moore, MD, MS, of the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma. Dr. Moore is being recognized for her remarkable leadership. She has not only been at the vanguard of novel therapeutic development that has impacted the standard of care for ovarian cancer patients but has also mentored dozens of clinical and translational investigators who have gone on to advance research through notable accomplishments of their own. She has also contributed extensively to the field as an author, with her work appearing in more than 400 peer-reviewed publications.

Dr. Moore is the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center. She also serves as the Associate Director of Clinical Research and Deputy Director of OU Health Stephenson Cancer Center.

The Rosalind Franklin Prize for Excellence in Ovarian Cancer Research is a $10,000 annual prize in recognition of contributions to basic science, translational, or clinical research in ovarian cancer. It is named for Dr. Rosalind Franklin, a pioneering molecular biologist who played a vital role in discovering the structure of DNA before her death of ovarian cancer at age 37.

Click here to view the full article.

CLINICAL TRIALS

The GOG Partners Program is currently recruiting for 22 clinical trials

- 14 Ovary
- 1 Cervix
- 7 Endometrium

To search active trials visit our website by clicking Clinical Trials button below.

Top 50 Recruiting Sites GOG Partners/NRG Combined

1. The Ohio State University Comprehensive Cancer Center
2. University of Oklahoma Health Sciences Center
3. Women & Infants Hospital
4. University of Virginia
5. Memorial Sloan Kettering Cancer Center
6. NYU Langone Medical Center - NYU Clinical
Cancer Center - Womens Cancer Program
7. Washington University School of Medicine
8. Georgia Regents/Augusta University
9. University of Rochester
10. Oklahoma Cancer Specialists and Research Institute, LLC
11. HonorHealth Research and Innovation Institute - USO
12. Froedtert and The Medical College of Wisconsin
13. University of Colorado Hospital - Anschutz Cancer Pavilion
14. Virginia Commonwealth University
15. Yale University
16. Abington Memorial Hospital - Asplundh Cancer Pavilion/Thomas Jefferson
17. University of Alabama at Birmingham
18. University of Chicago Medical Center
19. New Mexico Cancer Care Alliance/University of New Mexico Comprehensive Cancer Center
20. Duke University Medical Center
21. Western Pennsylvania Hospital/West Penn Hospital
23. Rutgers Cancer Institute of NJ
24. UCLA Johnson Comprehensive Cancer Center
25. The Blavatnik Family - Chelsea Medical Center at Mount Sinai
26. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
27. Cleveland Clinic Foundation
28. University of Washington Fred Hutchinson Cancer Center (FHCC)/Seattle Cancer Care Alliance
29. University of Cincinnati
30. Arizona Oncology Associates, PC - HOPE - USO
31. University of Iowa Hospitals and Clinics
32. Texas Oncology - Fort Worth - USO
33. Magee Women's Hospital - UPMC
34. Advent Health Orlando
35. Northwestern University
36. Texas Oncology, P.A., San Antonio Medical Center - USO
37. University of Pennsylvania
38. Women's Cancer Care Associates, LLC
39. Moffitt Cancer Center
40. University of Texas Southwestern Medical Center
41. Nebraska Methodist Hospital
42. University of Wisconsin
43. Indiana University
44. University of Michigan
45. Huntsman Cancer Institute
46. Center of Hope
47. Carilion Clinic Gynecologic Oncology
48. Baystate Medical Center
49. Avera Cancer Institute
50. University of California San Diego Moores Cancer Center

UPCOMING INDUSTRY MEETINGS

ASCO Annual Meeting

The 2024 ASCO Annual Meeting will be held on May 31 - June 4, 2024 in Chicago, IL, at the McCormick Place Convention Center. This year's meeting is only available in person.

Join fellow oncology professionals at the 2024 ASCO Annual Meeting – a unique and unparalleled opportunity to connect with one of the largest, most diverse audiences in the world.
global cancer care.

Click Here for more information on the ASCO Annual Meeting.

---

### WAGO Annual Meeting

The 2024 WAGO Annual Meeting will be held on **June 12 - 15, 2024 in Seattle, WA** at the Fairmont Olympic Hotel.

Click Here for more information on the WAGO Annual Meeting.

---

### ESMO Gynaecological Cancers Congress

The 2024 ESMO Gynaecological Cancers Congress will be held on **June 20-22, 2024 in Florence, Italy**.

ESMO Gynaecological Cancers has become an essential annual appointment for oncology professionals treating patients with such malignancies – the place to learn the latest promising news, acquire high quality education and exchange ideas.

Click Here for more information on the ESMO Gynaecological Cancers Annual Congress.

---

### NRG Summer Semi-Annual Meeting

The 2024 Summer NRG Semi-Annual Meeting will be held on **July 25 - 27, 2024 in Denver, CO** at the Sheraton Denver Downtown Hotel.

Click Here for more information on the NRG Semi-Annual Meeting.

---

### The GOG Highlight Reel - July 2024

The GOG Highlight Reel will be held on **Saturday July 27, 2024 in Denver, CO**, at the Sheraton Denver Downtown Hotel, in conjunction with the NRG Summer Semi-Annual Meeting.

---

### IGCS 2024 Annual Global Meeting

The IGCS 2024 Annual Global Meeting will be held on **October 16 - 18, 2024 in Dublin, Ireland**.

The IGCS Meeting is a platform for exchanging insights, sharing research findings, and discussing best practices. It's an opportunity to build professional networks, foster collaborations, and learn from some of the brightest minds in the field.

Don't miss the chance to be part of this global community striving to make a difference in the lives of women affected by gynecologic cancers!

Click here for more information on the IGCS 2024 Annual Global Meeting.

**IGCS 2024 abstract and surgical film deadline is April 30, 2024**

Click here to submit and contribute your research to IGCS 2024.
Evolution of the Care of Patients With Advanced Ovarian Cancer

Join Drs. Ursula Matulonis and Brad Monk for a live, case-based webinar focusing on the frontline management of patients with advanced ovarian cancer. Treatment decision-making in ovarian cancer is becoming increasingly complex with the introduction of new therapies and modifications to indications of existing therapies.

Through the discussion of real-world case scenarios, Drs. Matulonis and Monk will review the latest clinical trial data, patient- and disease-related characteristics that influence treatment selection, identification and management of treatment-related adverse events, and shared decision-making. Don't miss this exciting activity!

Click here to access the recording.

ADCs First to Cervix Cancer and Here to Stay: Understanding Provider and Patient Perspectives

an Industry Supported Symposium at the 2024 SGO Annual Meeting on Women’s Cancer

Access to Symposium Recording
Please click here to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the ADCs First to Cervix Cancer and Here to Stay: Understanding Provider and Patient Perspectives symposium recording.

Access to Symposium Presentations
Please click here to access the presentation files on the GOG Website.

Course Objectives
- Review the current landscape for the treatment of recurrent cervix cancer based on pivotal clinical trial data and insights from 2023
- Understand the role of ADC in cervix cancer, and how to educate patients on this novel treatment option
- Review and incorporate updated data in treatment decision making through case based learning
- Understand the patient perspective with respect to receiving treatments in recurrent cervix cancer

This symposium was developed by The GOG Foundation, Inc. in partnership with Seagen, Inc. and Genmab
It's A Whole New World: Navigating Therapeutic Options for Endometrial Cancer Enduring Educational Materials

an Industry Supported Symposium at the 2024 SGO Winter Meeting

Access to Symposium Recording
Please [click here](#) to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the It's A Whole New World: Navigating Therapeutic Options for Endometrial Cancer Enduring Educational Materials symposium recording.

Access to Symposium Presentations
Please [click here](#) to access the presentation file on the GOG Website.

Course Objectives:
- Review the current landscape for the treatment of advanced stage or recurrent endometrial cancer based on pivotal clinical trials and insights in 2023.
- Discuss biomarker-based strategies to direct chemotherapy, radiation, combined chemoradiation, and biologic-targeted therapies.
- Highlight novel therapies and current clinical trials for endometrial cancer.
- Decipher how to best treat patients based on debates and discussion from Expert Faculty.

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: AstraZeneca, GSK, and Karyopharm

The 3 E’s of ICI in endometrial cancer:
emergence, evolution, and expansion
an Industry Supported Symposium at the 2023 IGCS Annual Global Meeting

ACCESS TO SYMPOSIUM RECORDING
Please click here to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the 3 E's of ICI in endometrial cancer: emergence, evolution, and expansion symposium recording.

ACCESS TO SYMPOSIUM PRESENTATIONS
Please click here to access the presentation files on the GOG website.

---

Target Practice: Zeroing in and Eliminating Ovarian Cancer. A course to review and understand the ADC opportunities that exist in Ovarian Cancer

an Industry Supported Symposium at the 2023 IGCS Annual Global Meeting

ACCESS TO SYMPOSIUM RECORDING
Please click here to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the Target Practice: Zeroing in and Eliminating Ovarian Cancer. A course to review and understand the ADC opportunities that exist in Ovarian Cancer symposium recording.

ACCESS TO PRESENTATIONS
Please click here to access the presentation file on the GOG website.

Course Objectives:
- Review and understand all ADC Opportunities that exist in ovarian cancer patient care management.
- Understand the components of each unique agent and how to mitigate any adverse reactions.
- Discuss ADC targets and how to prioritize targets for your patient.
- Outline the ongoing trials studying ADCs in Ovarian Cancer.

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: ImmunoGen, Mersana, and Novocure.
Join the Conversation: Incorporating Breakthrough Cervical Cancer Data into Practice

an Industry Supported Symposium at the 2023 IGCS Annual Global Meeting

TO ACCESS SYMPOSIUM RECORDING
Please click here to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the Join the Conversation: Incorporating Breakthrough Cervical Cancer Data into Practice symposium recording.

TO ACCESS SYMPOSIUM PRESENTATIONS
Please click here to access the presentation files on the GOG website.

The Evolving Landscape in Molecular-Driven Investigational Therapies for Advanced Endometrial Cancer

an Industry Supported Symposium at the 2023 IGCS Annual Global Meeting

TO ACCESS SYMPOSIUM RECORDING
Please click here to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to The Evolving Landscape in Molecular-Driven Investigational Therapies for Advanced Endometrial Cancer symposium recording.

TO ACCESS SYMPOSIUM PRESENTATIONS
Please click here to access the presentation files on the GOG website.

Overview
This sixty-minute virtual symposium will discuss emerging molecular-driven therapeutics in
advanced endometrial cancer (EC). The overall goal is to educate on how molecular profiling is driving advancement in EC research and how the development landscape is evolving. Expert physicians will have a robust discussion to showcase the latest clinical trial data and potential impact on future treatment.

An Evolving Frontier - Understanding Novel Treatment Options for The Management of Advanced Stage or Recurrent Endometrial Cancers

First Presentation:
The Evolving Treatment Landscape for The Management of Endometrial Cancer

Presented By:
Ramez N. Eskander, MD
UC San Diego School of Medicine, San Diego, CA, USA

How To Access The Recording
When viewing the recording, all registrants must sign in to Education360 Learning Portal with their IGCS username and password. If you receive email communications from IGCS, you already have an account.

If you have forgotten your password, please click here.

For further assistance with your IGCS account, contact igcs@igcs.org.

If you are unsure of your IGCS account login information, please contact igcs@igcs.org.

Eisai has sponsored this initiative with IGCS and had no input into or influence over the content.

View Recording

PHILANTHROPY

New Horizons Gynecologic Cancer Research Fund

The New Horizons Gynecologic Cancer Research Fund is
the philanthropic arm for The GOG Foundation, Inc. (GOG-F). Donations allow the GOG-F to enrich efforts to develop and deliver essential research tools needed to further clinical trial development and translational research programs.

Donations from individuals, corporations, and foundations directly fund the GOG-F educational and research initiatives. Together, we collaborate with industry to find new treatments, and more effective prevention while promoting excellence in scientific research in the field of gynecologic malignancies.

Each donation received will go directly to provide:
- Much needed resources to effectively work towards the prevention and treatment of gynecologic malignancies
- Accessible research funding
- Ability to mentor New Investigators through fellowship awards
- Opportunity to raise public awareness through education and research
- Translational medicine initiatives across the disease committees

Click the Support Our Mission button below to make a donation today!

Click the Support Our Mission button below to make a donation today!

**LET'S GET SOCIAL**

Participate in the “What GOG Means to ME” social media campaign!

Please email Lindsey Moeller at lmoeller@gog.org and include the following information:

- Quote: No more than 35 words indicating what GOG means to you
- Current Headshot (Jpg or PNG format)
- Current Title/Role
- Institution
- Social Tags: Please provide how we can find you on each of the social platforms so we can tag you when we post.

**CONTACT US**

How Can We Help?

The GOG Partners Connection Quarterly Newsletter is produced by the GOG Foundation Communications Committee.

Please contact us at info@gog.org with any questions or suggestions regarding future content.